

(10) International Publication Number
WO 2016/020320 A1(43) International Publication Date
11 February 2016 (11.02.2016)

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 35/00 (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:

PCT/EP2015/067804

(22) International Filing Date:

3 August 2015 (03.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14179692.0 4 August 2014 (04.08.2014) EP
15159342.3 17 March 2015 (17.03.2015) EP(71) Applicant: BAYER PHARMA AKTIENGESELL-
SCHAFT [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors: WORTMANN, Lars; Kastanienallee 103, 10435 Berlin (DE). LÜCKING, Ulrich; Paula-Fürst-Str. 2, 10317 Berlin (DE). LEFRANC, Julien; Fischerinsel 13, Apt. 18/124, 10179 Berlin (DE). BRIEM, Hans; Emser Str. 3, 10719 Berlin (DE). KOPPITZ, Marcus; Elsenbruchstr. 34A, 13467 Berlin (DE). EIS, Knut; Fichtenweg 1, 13587 Berlin (DE). VON NUSSBAUM, Franz; Kreuzritterstr. 3, 13465 Berlin (DE). BADER, Benjamin; Hillmannstr. 14, 13467 Berlin (DE). WENGNER, Antje Margret; Borkumstr. 12 e, 13189 Berlin (DE). SIEMEISTER, Gerhard; Reimerswalder Steig 26, 13503 Berlin (DE). BONE, Wilhelm; Drewitzer Str. 46, 13467 Berlin (DE). LIENAU, Philip; Jahnstr. 13, 10967 Berlin (DE). GRUDZINSKA-GOEBEL, Joanna; An den Eldenaer Höfen 37, 10247 Berlin (DE). MOOSMAYER, Dieter; Wöhlerstr. 11, 10115 Berlin (DE). EBERSPÄCHER, Uwe; Zernsdorfer Weg 59, 13465 Berlin (DE). SCHICK, Hans; Parkstr. 36, 13086 Berlin (DE).

(74) Agent: BIP PATENTS; c/o Bayer Intellectual Property GmbH, Alfred-Nobel-Str. 10, 40789 Monheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))


Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES



(I)



(Ib)

(57) Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.